Drugs / ION337
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07531745 | May 2026 → Dec 2030 expected | Dravet syndrome | Ionis Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Ionis Pharmaceuticals | Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome ionis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION337 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07531745 ↗ |
| Route | Intrathecal | “Intrathecally-Administered ION337” NCT07531745 ↗ |